Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06026319 · ClinicalTrials.gov registry record · Phase 1

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

A Phase 1 study of Diffuse Large B Cell Lymphoma and Non-Hodgkin Lymphoma, sponsored by Marcela V. Maus, M.D.,Ph.D..

Recruiting
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT06026319 is a Phase 1 study of Diffuse Large B Cell Lymphoma and Non-Hodgkin Lymphoma that is actively recruiting participants, run by Marcela V. Maus, M.D.,Ph.D.. The registered enrollment target is 24 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06026319, a Phase 1 study of Diffuse Large B Cell Lymphoma and Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Marcela V. Maus, M.D.,Ph.D..

RECRUITING
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: * CD79b-19 CAR T cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process

Conditions Studied

Diffuse Large B Cell Lymphoma Non-Hodgkin Lymphoma Mantle Cell Lymphoma Follicular Lymphoma Marginal Zone Lymphoma High Grade B-Cell Lymphoma Refractory Non-Hodgkin Lymphoma Relapsed Non-Hodgkin Lymphoma Primary Mediastinal Large B-cell Lymphoma (PMBCL) Grade 3b Follicular Lymphoma

Interventions

  • DRUG Cyclophosphamide
  • DRUG Fludarabine
  • DRUG CD79b-19 CAR T cells

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2023-10-26
Est. Completion 2028-01-01
Phase Phase 1

Sponsor

Marcela V. Maus, M.D.,Ph.D.

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06026319

The ClinicalTrials.gov registry entry for NCT06026319 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (89% lower). The listed sponsor is Marcela V. Maus, M.D.,Ph.D., which has 8 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.

NCT06026319 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06026319 about?

NCT06026319 is a clinical study titled "CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma". This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: * CD79b-19 CAR T cells * Fludarabine and Cycloph...

What is the current status of trial NCT06026319?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2023-10-26. Estimated completion is 2028-01-01.

What conditions does trial NCT06026319 study?

This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma.

What interventions are being tested in trial NCT06026319?

The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), CD79b-19 CAR T cells (DRUG).

Who is sponsoring clinical trial NCT06026319?

This trial is sponsored by Marcela V. Maus, M.D.,Ph.D., which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06026319 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diffuse Large B Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diffuse Large B Cell Lymphoma

All registered trials for this condition

Non-Hodgkin Lymphoma

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.